These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 18519868)
1. To test or not to test: NMO-IgG and optic neuritis. Giovannoni G Neurology; 2008 Jun; 70(23):2192-3. PubMed ID: 18519868 [No Abstract] [Full Text] [Related]
2. Should most patients with optic neuritis be tested for neuromyelitis optica antibodies and should this affect their treatment? Galetta SL; Cornblath WT J Neuroophthalmol; 2010 Dec; 30(4):376-8; discussion 378-9. PubMed ID: 21107126 [No Abstract] [Full Text] [Related]
3. NMO-IgG predicts the outcome of recurrent optic neuritis. Matiello M; Lennon VA; Jacob A; Pittock SJ; Lucchinetti CF; Wingerchuk DM; Weinshenker BG Neurology; 2008 Jun; 70(23):2197-200. PubMed ID: 18434643 [TBL] [Abstract][Full Text] [Related]
4. Neuromyelitis optica antibodies in patients with severe optic neuritis in China. Lai C; Tian G; Takahashi T; Liu W; Yang L; Zhang X J Neuroophthalmol; 2011 Mar; 31(1):16-9. PubMed ID: 21150455 [TBL] [Abstract][Full Text] [Related]
5. Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations. Hamnik SE; Hacein-Bey L; Biller J; Gruener G; Jay W Semin Ophthalmol; 2008; 23(3):191-200. PubMed ID: 18432545 [TBL] [Abstract][Full Text] [Related]
6. Differential regulation of IgG-NMO autoantibodies on S100Beta protein and disability in relapsing neuromyelitis optica. Robinson-Agramonte MA; Gonçalves CA; Portela LV; Saiz-Hinarejos A; Oses JP; Motta LS; Muller AP; Marquez Gonzalez ME; Souza DO Neuroimmunomodulation; 2010; 17(3):177-9. PubMed ID: 20134196 [TBL] [Abstract][Full Text] [Related]
11. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077 [TBL] [Abstract][Full Text] [Related]
12. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309 [TBL] [Abstract][Full Text] [Related]
17. NMO-IgG in the diagnosis of neuromyelitis optica. Jarius S; Franciotta D; Bergamaschi R; Wright H; Littleton E; Palace J; Hohlfeld R; Vincent A Neurology; 2007 Mar; 68(13):1076-7. PubMed ID: 17287449 [No Abstract] [Full Text] [Related]
18. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. Saiz A; Zuliani L; Blanco Y; Tavolato B; Giometto B; Graus F; J Neurol; 2007 Sep; 254(9):1233-7. PubMed ID: 17401734 [TBL] [Abstract][Full Text] [Related]
19. [Inflammation of the optic nerve: when it should be considered as neuromyelitis optica--the experience of the Department of Neurology at Hadassah Hospital]. Vaknin-Dembinsky A; Levin N; Raz N; Abramsky O; Karussis D; Brill L; Petrou P; Ovadia H Harefuah; 2013 Feb; 152(2):101-5, 122. PubMed ID: 23513502 [TBL] [Abstract][Full Text] [Related]
20. [Neuromyelitis optica is a frequently seen inflammatory demyelinating disease]. Asgari N; Skejø HP; Lillevang ST; Stenager E Ugeskr Laeger; 2013 May; 175(19):1331-5. PubMed ID: 23663369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]